AlphAIAlphAI — Financial news for AI agents
investing.comSEP 212 min read$CADL

Candel Therapeutics stock jumps on BofA upgrade to buy

Candel Therapeutics (CADL) shares rose 9.3% premarket after BofA Securities upgraded the stock to Buy and raised the price target to $18.00 from $12.00, citing positive outlook for the biotech sector and key catalysts.

Original reporting
investing.com
Published Sep 21, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$CADL
Bullish
high confidence
Mentioned
$CADL
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CADLBullishMed
01

Why it matters

The upgrade provides a fresh catalyst that could attract short‑term buying pressure.

02

Market read

The news is a primary disclosure of an analyst upgrade, generating immediate price impact.

03

What to watch

No new clinical data released; move is purely analyst sentiment.

Relevance 7/10Novelty 7/10Timing: premarket today

Background

Candel Therapeutics is a Nasdaq‑listed biotech; the upgrade is part of BofA's sector outlook.

Company-level read

Ticker impact

$CADLBullishHigh confidence
Context

BofA upgraded Candel Therapeutics to Buy and raised price target to $18, driving a 9.3% pre‑market jump.

Expected impact

short‑term rally, potential continuation if earnings remain strong

Evidence & confidence

Upgrade is fresh, price target increased 50%, and stock already moved 9% pre‑market, indicating strong trader interest.

Market effects

Sector

Biotech sector may see broader optimism as BofA highlights it as a standout sector.

Regional

US biotech stocks could benefit from spillover buying.

Global

Limited to investors focused on US‑listed biotech equities.

Counterpoint

What could challenge this read

Upgrade may be premature if upcoming trial data disappoints; price could retrace.

Key entities

  • company
    Candel Therapeutics Inc.

    Biotech firm (NASDAQ:CADL) receiving BofA upgrade.

  • analyst
    BofA Securities

    Investment bank that raised CADL's rating and price target.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 22
$CADLMedAI 8/10

Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data

Jefferies initiated Candel Therapeutics (NASDAQ:CADL) with a buy rating and $25 price target, citing positive Phase III prostate cancer data. The stock trades at $8.37, with analyst targets ranging from $15 to $29. The company has a strong financial position and plans a 2026 biologics license application. Recent data showed a hazard ratio of 0.70 and 80.4% negative biopsy rate. Other analysts also reiterated buy ratings and raised price targets.

investing.com2 min
OCT 2
$CADLHighAI 8/10

H.C. Wainwright reiterates Candel Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.

investing.com2 min
OCT 1
$CADLMedAI 9/10

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Candel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.

globenewswire.com3 min
SEP 30
$CADLMedAI 8/10

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics (CADL) reported positive data from its phase 2 PrTK05 trial, showing durable immune activation in intermediate-risk prostate cancer patients. Aglatimagene treatment reduced recurrence risk by 41% vs. placebo. The company plans to submit a BLA in Q4 2026. Data will be presented at future scientific meetings.

globenewswire.com3 min